Provided by Tiger Fintech (Singapore) Pte. Ltd.

OnKure Therapeutics, Inc.

4.61
-0.0100-0.22%
Post-market: 4.610.00000.00%17:00 EDT
Volume:39.00K
Turnover:178.63K
Market Cap:61.49M
PE:-0.30
High:4.68
Open:4.67
Low:4.45
Close:4.62
Loading ...

Company Profile

Company Name:
OnKure Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
46
Office Location:
6707 Winchester Circle,Suite 400,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Directors

Name
Position
Gregory J. Flesher
President, Chief Executive Officer and Director
Michael Grey
Executive Chairman
Bali Muralidhar
Director
Edward T. Mathers
Director
Eric M. Dube
Director
Kenneth Harrison
Director
Lon Cardon
Director
Niall O'Donnell
Director
Stacey D. Seltzer
Director

Shareholders

Name
Position
Gregory J. Flesher
President, Chief Executive Officer and Director
Michael Cruse
Senior Vice President, Corporate Operations
Vineet R. Jindal
Chief Financial Officer
Alejandro Dorenbaum
Chief Medical Officer
Michael Grey
Executive Chairman
Wendy Johnson
Chief Development Officer